Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis
- PMID: 22013437
- PMCID: PMC3195304
- DOI: 10.1155/2011/378278
Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis
Abstract
Dysregulation of iron metabolism has been observed in patients with neurodegenerative diseases (NDs). Utilization of several importers and exporters for iron transport in brain cells helps maintain iron homeostasis. Dysregulation of iron homeostasis leads to the production of neurotoxic substances and reactive oxygen species, resulting in iron-induced oxidative stress. In Alzheimer's disease (AD) and Parkinson's disease (PD), circumstantial evidence has shown that dysregulation of brain iron homeostasis leads to abnormal iron accumulation. Several genetic studies have revealed mutations in genes associated with increased iron uptake, increased oxidative stress, and an altered inflammatory response in amyotrophic lateral sclerosis (ALS). Here, we review the recent findings on brain iron metabolism in common NDs, such as AD, PD, and ALS. We also summarize the conventional and novel types of iron chelators, which can successfully decrease excess iron accumulation in brain lesions. For example, iron-chelating drugs have neuroprotective effects, preventing neural apoptosis, and activate cellular protective pathways against oxidative stress. Glial cells also protect neurons by secreting antioxidants and antiapoptotic substances. These new findings of experimental and clinical studies may provide a scientific foundation for advances in drug development for NDs.
Figures

Similar articles
-
The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging.Cells. 2023 Feb 27;12(5):763. doi: 10.3390/cells12050763. Cells. 2023. PMID: 36899898 Free PMC article. Review.
-
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.Free Radic Biol Med. 2013 Sep;62:52-64. doi: 10.1016/j.freeradbiomed.2013.01.017. Epub 2013 Jan 30. Free Radic Biol Med. 2013. PMID: 23376471 Review.
-
Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.J Neural Transm (Vienna). 2020 Feb;127(2):189-203. doi: 10.1007/s00702-019-02138-1. Epub 2020 Jan 7. J Neural Transm (Vienna). 2020. PMID: 31912279 Review.
-
Role of Alcohol Drinking in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.Int J Mol Sci. 2020 Mar 27;21(7):2316. doi: 10.3390/ijms21072316. Int J Mol Sci. 2020. PMID: 32230811 Free PMC article. Review.
-
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.Mech Ageing Dev. 2005 Feb;126(2):317-26. doi: 10.1016/j.mad.2004.08.023. Mech Ageing Dev. 2005. PMID: 15621213 Review.
Cited by
-
Residential exposure to electromagnetic fields and risk of amyotrophic lateral sclerosis: a dose-response meta-analysis.Sci Rep. 2021 Jun 7;11(1):11939. doi: 10.1038/s41598-021-91349-2. Sci Rep. 2021. PMID: 34099747 Free PMC article.
-
Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases.Int J Mol Sci. 2024 Sep 23;25(18):10187. doi: 10.3390/ijms251810187. Int J Mol Sci. 2024. PMID: 39337671 Free PMC article. Review.
-
Hepcidin Plays a Key Role in 6-OHDA Induced Iron Overload and Apoptotic Cell Death in a Cell Culture Model of Parkinson's Disease.Parkinsons Dis. 2016;2016:8684130. doi: 10.1155/2016/8684130. Epub 2016 May 19. Parkinsons Dis. 2016. PMID: 27298749 Free PMC article.
-
Polyphenol Stilbenes: Molecular Mechanisms of Defence against Oxidative Stress and Aging-Related Diseases.Oxid Med Cell Longev. 2015;2015:340520. doi: 10.1155/2015/340520. Epub 2015 Jun 9. Oxid Med Cell Longev. 2015. PMID: 26180583 Free PMC article. Review.
-
Gene expression analysis reveals the dysregulation of immune and metabolic pathways in Alzheimer's disease.Oncotarget. 2016 Nov 8;7(45):72469-72474. doi: 10.18632/oncotarget.12505. Oncotarget. 2016. PMID: 27732949 Free PMC article.
References
-
- Andrews NC. Disorders of iron metabolism. New England Journal of Medicine. 1999;341(26):1986–1995. - PubMed
-
- Flanagan PR. Intestinal Iron Metabolism and Absorption. New York, NY, USA: CRC Press; 1990. (edited by P. Ponka, H. M. Schulman, R. C. Woodworth).
-
- Oshiro S, Kawahara M, Mika S, et al. Aluminum taken up by transferrin-independent iron uptake affects the iron metabolism in rat cortical cells. Journal of Biochemistry. 1998;123(1):42–46. - PubMed
-
- Oshiro S, Nakamura Y, Ishige R, Hori M, Nakajima H, Gahl WA. Reduction site of transferrin-dependent and transferrin-independent iron in cultured human fibroblasts. Journal of Biochemistry. 1994;115(5):849–852. - PubMed
-
- McKie AT, Barrow D, Latunde-Dada GO, et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science. 2001;291(5509):1755–1759. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous